Pierre Socha
Principal
Pierre joined Amadeus Capital Partners in 2012. Pierre has a current investment focus on digital health, medical technology, AI and machine learning and cybersecurity. He is a non-executive director on the boards of Inotec, Repositive, Doctify, Congenica and oversees Amadeus’s investments in PhoreMost, Organox and Antidote (formerly TrialReach).
Pierre brings operational experience to these investments, having managed the growth of several life science businesses in Asia and Europe. During a decade at biotech company Avesthagen, he guided the group’s strategy and European activities, contributing to acquisitions, joint ventures and exits.
Pierre started his career as an auditor with KPMG in France and subsequently worked as a financial engineer at Natixis and as a research fellow in health and urban microeconomics.
Pierre is French and holds an MSc in Environmental Economics (Hons.-SciencesEco) from Université de Provence, France and a BSc in Finance & Econometrics (Math Spe.-SciencesEco) from Université Louis Pasteur, France. He has attended executive programs at Harvard, MIT and Stanford.
Pierre speaks French and English and understands German.
Pierre is the Amadeus contact for
Meet Pierre at:
19th November 2019
LSX Inv€$tival Showcase 2019
Pierre Socha will be attending the fourth annual Investival Showcase in London. A multi-streamed showcase of early, growth stage and public life science and health technology companies.
20th November 2019
SVC2UK: London Thought Leadership
Pierre Socha will be attending the SVC2UK: London Thought Leadership 2019 event in London. The event acts as the pinnacle of the 2019 SVC2UK journey as they highlight this year’s mission, critical to change our perspective about the power and potential of purpose-driven businesses.
More from Pierre
Blog: 23rd May 2017
Genomics: Live Long & Federate!
Blog: 24th February 2017
Genomics | Reaching Base Camp
